Secretory leukocyte peptidase inhibitor as a dynamic radiotherapy response biomarker in esophageal squamous cell carcinoma

Abstract

Esophageal cancer is the seventh leading cause of cancer-related deaths, with most cases diagnosed at locally advanced stages. Chemoradiotherapy is one of the most effective treatments for these patients. However, high rates of recurrence persist, highlighting the need for more reliable prognostic biomarkers. In this study, we identified immune-related prognostic genes through bulk (n = 119) and single-cell (n = 60) transcriptomic analyses. We then used Western blotting, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence to preliminarily investigate the potential biological functions of the candidate biomarker. The clinical prognostic utility of the candidate biomarker was validated in an independent cohort (n = 91) via ELISA of serum samples collected before and during chemoradiotherapy. The results showed that low expression of the secretory leukocyte peptidase inhibitor (SLPI) significantly correlated with tumor progression and poor prognosis. In epithelial cells, reduced SLPI expression was associated with decreased activation of differentiation-related pathways. Furthermore, SLPI expression levels were found to influence fibroblast phenotypes, with exogenous SLPI inhibiting the NF-κB pathway and restoring fibroblast quiescence. The results of ELISA showed that dynamic changes in serum SLPI levels during chemoradiotherapy serve as an independent prognostic factor. In conclusion, serum SLPI levels represent an easy-to-detect biomarker for dynamically monitoring the efficacy of chemoradiotherapy.

Keywords

esophageal squamous cell carcinoma / secretory leukocyte peptidase inhibitor / transcriptome / radiotherapy / prognosis

References

[1] Bray F , Laversanne M , Sung H , Ferlay J , Siegel RL , Soerjomataram I , Jemal A . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229–263

[2] Li Q , Xia C , Li H , Yan X , Yang F , Cao M , Zhang S , Teng Y , He S , Cao M , Chen W . Disparities in 36 cancers across 185 countries: secondary analysis of global cancer statistics. Front Med 2024; 18(5): 911–920

[3] Morgan E , Soerjomataram I , Rumgay H , Coleman HG , Thrift AP , Vignat J , Laversanne M , Ferlay J , Arnold M . The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 2022; 163(3): 649–658.e2

[4] Liu Z , Zhao Y , Kong P , Liu Y , Huang J , Xu E , Wei W , Li G , Cheng X , Xue L , Li Y , Chen H , Wei S , Sun R , Cui H , Meng Y , Liu M , Li Y , Feng R , Yu X , Zhu R , Wu Y , Li L , Yang B , Ma Y , Wang J , Zhu W , Deng D , Xi Y , Wang F , Li H , Guo S , Zhuang X , Wang X , Jiao Y , Cui Y , Zhan Q . Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell 2023; 41(1): 181–195.e9

[5] Liu J , Yue J , Xing L , Yu J . Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer. Front Med 2013; 7(2): 172–179

[6] Yang H , Wang F , Hallemeier CL , Lerut T , Fu J . Oesophageal cancer. Lancet 2024; 404(10466): 1991–2005

[7] Xie FJ , Zheng QQ , Qin J , Zhang LL , Han N , Mao WM . Autophagy inhibition stimulates apoptosis in oesophageal squamous cell carcinoma treated with fasudil. J Cancer 2018; 9(6): 1050–1056

[8] Li C , Wang X , Wang L , Chen J , Zhang W , Pang Q , Zhao Y , Sun X , Zhang K , Li G , Li L , Qiao X , Liu M , Wang Y , Deng L , Wang W , Bi N , Zhang T , Deng W , Ni W , Chang X , Han W , Zhou Z , Liang J , Feng Q , Wang L , Chen D , Lv J , Zhu S , Han C , Xiao Z . Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG survey. Acta Oncol 2021; 60(5): 627–634

[9] An L , Li M , Jia Q . Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma. Mol Cancer 2023; 22(1): 140

[10] Herskovic A , Martz K , al-Sarraf M , Leichman L , Brindle J , Vaitkevicius V , Cooper J , Byhardt R , Davis L , Emami B . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326(24): 1593–1598

[11] Welsh J , Settle SH , Amini A , Xiao L , Suzuki A , Hayashi Y , Hofstetter W , Komaki R , Liao Z , Ajani JA . Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012; 118(10): 2632–2640

[12] Sudo K , Xiao L , Wadhwa R , Shiozaki H , Elimova E , Taketa T , Blum MA , Lee JH , Bhutani MS , Weston B , Ross WA , Komaki R , Rice DC , Swisher SG , Hofstetter WL , Maru DM , Skinner HD , Ajani JA . Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014; 32(30): 3400–3405

[13] Hulshof MCCM , Geijsen ED , Rozema T , Oppedijk V , Buijsen J , Neelis KJ , Nuyttens JJME , van der Sangen MJC , Jeene PM , Reinders JG , van Berge Henegouwen MI , Thano A , van Hooft JE , van Laarhoven HWM , van der Gaast A . Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study). J Clin Oncol 2021; 39(25): 2816–2824

[14] Kim JY , Yun JK , Kim YH , Park SI , Lee JH , Jung HY , Lee GH , Song HJ , Kim DH , Choi KD , Ahn JY , Kim SB , Cho KJ , Ryu JS , Kim JH , Kang J , Park SR , Kim HR . Prognostic impact of inflammation-based factors in patients with esophageal squamous cell carcinoma achieving pathological complete response after neoadjuvant chemoradiotherapy followed by surgery. Ann Surg Oncol 2024; 31(10): 6662–6672

[15] Yodying H , Matsuda A , Miyashita M , Matsumoto S , Sakurazawa N , Yamada M , Uchida E . Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2016; 23(2): 646–654

[16] Shi Y , Shen G , Zeng Y , Ju M , Chen X , He C , Liang L , Ge X , Sun X , Di X . Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy. Int Immunopharmacol 2023; 123: 110773

[17] Wang Y , Wang M , Wu HX , Xu RH . Advancing to the era of cancer immunotherapy. Cancer Commun (Lond) 2021; 41(9): 803–829

[18] Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 2020; 11(1): 3801

[19] Luo H , Lu J , Bai Y , Mao T , Wang J , Fan Q , Zhang Y , Zhao K , Chen Z , Gao S , Li J , Fu Z , Gu K , Liu Z , Wu L , Zhang X , Feng J , Niu Z , Ba Y , Zhang H , Liu Y , Zhang L , Min X , Huang J , Cheng Y , Wang D , Shen Y , Yang Q , Zou J , Xu RH; ESCORT-1st Investigators . Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 2021; 326(10): 916–925

[20] Wang ZX , Cui C , Yao J , Zhang Y , Li M , Feng J , Yang S , Fan Y , Shi J , Zhang X , Shen L , Shu Y , Wang C , Dai T , Mao T , Chen L , Guo Z , Liu B , Pan H , Cang S , Jiang Y , Wang J , Ye M , Chen Z , Jiang D , Lin Q , Ren W , Wang J , Wu L , Xu Y , Miao Z , Sun M , Xie C , Liu Y , Wang Q , Zhao L , Li Q , Huang C , Jiang K , Yang K , Li D , Liu Y , Zhu Z , Chen R , Jia L , Li W , Liao W , Liu HX , Ma D , Ma J , Qin Y , Shi Z , Wei Q , Xiao K , Zhang Y , Zhang Y , Chen X , Dai G , He J , Li J , Li G , Liu Y , Liu Z , Yuan X , Zhang J , Fu Z , He Y , Ju F , Liu Z , Tang P , Wang T , Wang W , Zhang J , Luo X , Tang X , May R , Feng H , Yao S , Keegan P , Xu RH , Wang F . Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 2022; 40(3): 277–288.e3

[21] Lu Z , Wang J , Shu Y , Liu L , Kong L , Yang L , Wang B , Sun G , Ji Y , Cao G , Liu H , Cui T , Li N , Qiu W , Li G , Hou X , Luo H , Xue L , Zhang Y , Yue W , Liu Z , Wang X , Gao S , Pan Y , Galais MP , Zaanan A , Ma Z , Li H , Wang Y , Shen L; ORIENT-15 study group . Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 2022; 377: e068714

[22] Charpentier M , Spada S , Van Nest SJ , Demaria S . Radiation therapy-induced remodeling of the tumor immune microenvironment. Semin Cancer Biol 2022; 86(Pt 2): 737–747

[23] Liu S , Wang W , Hu S , Jia B , Tuo B , Sun H , Wang Q , Liu Y , Sun Z . Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death Dis 2023; 14(10): 679

[24] Li S , Chen K , Sun Z , Chen M , Pi W , Zhou S , Yang H . Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity. Expert Rev Mol Med 2024; 26: e30

[25] Ji J , Ding K , Cheng B , Zhang X , Luo T , Huang B , Yu H , Chen Y , Xu X , Lin H , Zhou J , Wang T , Jin M , Liu A , Yan D , Liu F , Wang C , Chen J , Yan F , Wang L , Zhang J , Yan S , Wang J , Li X , Chen G . Radiotherapy-induced astrocyte senescence promotes an immunosuppressive microenvironment in glioblastoma to facilitate tumor regrowth. Adv Sci (Weinh) 2024; 11(15): 2304609

[26] Alaei S , Sadeghi B , Najafi A , Masoudi-Nejad A . LncRNA and mRNA integration network reconstruction reveals novel key regulators in esophageal squamous-cell carcinoma. Genomics 2019; 111(1): 76–89

[27] Zhang X , Peng L , Luo Y , Zhang S , Pu Y , Chen Y , Guo W , Yao J , Shao M , Fan W , Cui Q , Xi Y , Sun Y , Niu X , Zhao X , Chen L , Wang Y , Liu Y , Yang X , Wang C , Zhong C , Tan W , Wang J , Wu C , Lin D . Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nat Commun 2021; 12(1): 5291

[28] Chen L , Zhu S , Liu T , Zhao X , Xiang T , Hu X , Wu C , Lin D . Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression. Signal Transduct Target Ther 2023; 8(1): 453

[29] Li J , Miao B , Wang S , Dong W , Xu H , Si C , Wang W , Duan S , Lou J , Bao Z , Zeng H , Yang Z , Cheng W , Zhao F , Zeng J , Liu XS , Wu R , Shen Y , Chen Z , Chen S , Wang M; Hiplot Consortium . Hiplot: a comprehensive and easy-to-use web service for boosting publication-ready biomedical data visualization. Brief Bioinform 2022; 23(4): bbac261

[30] Hao Y , Hao S , Andersen-Nissen E , Mauck WM 3rd , Zheng S , Butler A , Lee MJ , Wilk AJ , Darby C , Zager M , Hoffman P , Stoeckius M , Papalexi E , Mimitou EP , Jain J , Srivastava A , Stuart T , Fleming LM , Yeung B , Rogers AJ , McElrath JM , Blish CA , Gottardo R , Smibert P , Satija R . Integrated analysis of multimodal single-cell data. Cell 2021; 184(13): 3573–3587.e29

[31] Becht EMcInnes LHealy JDutertre CAKwok IWHNg LGGinhoux FNewell EW. Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol 2019; 37: 38–44.

[32] Ma C , Yang C , Peng A , Sun T , Ji X , Mi J , Wei L , Shen S , Feng Q . Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment. Mol Cancer 2023; 22(1): 170

[33] Subramanian A , Tamayo P , Mootha VK , Mukherjee S , Ebert BL , Gillette MA , Paulovich A , Pomeroy SL , Golub TR , Lander ES , Mesirov JP . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102(43): 15545–15550

[34] Ashburner M , Ball CA , Blake JA , Botstein D , Butler H , Cherry JM , Davis AP , Dolinski K , Dwight SS , Eppig JT , Harris MA , Hill DP , Issel-Tarver L , Kasarskis A , Lewis S , Matese JC , Richardson JE , Ringwald M , Rubin GM , Sherlock G . Gene ontology: tool for the unification of biology. Nat Genet 2000; 25(1): 25–29

[35] Gene Ontology Consortium; Aleksander SA , Balhoff J , Carbon S , Cherry JM , Drabkin HJ , Ebert D , Feuermann M , Gaudet P , Harris NL , Hill DP , Lee R , Mi H , Moxon S , Mungall CJ , Muruganugan A , Mushayahama T , Sternberg PW , Thomas PD , Van Auken K , Ramsey J , Siegele DA , Chisholm RL , Fey P , Aspromonte MC , Nugnes MV , Quaglia F , Tosatto S , Giglio M , Nadendla S , Antonazzo G , Attrill H , Dos Santos G , Marygold S , Strelets V , Tabone CJ , Thurmond J , Zhou P , Ahmed SH , Asanitthong P , Luna Buitrago D , Erdol MN , Gage MC , Ali Kadhum M , Li KYC , Long M , Michalak A , Pesala A , Pritazahra A , Saverimuttu SCC , Su R , Thurlow KE , Lovering RC , Logie C , Oliferenko S , Blake J , Christie K , Corbani L , Dolan ME , Drabkin HJ , Hill DP , Ni L , Sitnikov D , Smith C , Cuzick A , Seager J , Cooper L , Elser J , Jaiswal P , Gupta P , Jaiswal P , Naithani S , Lera-Ramirez M , Rutherford K , Wood V , De Pons JL , Dwinell MR , Hayman GT , Kaldunski ML , Kwitek AE , Laulederkind SJF , Tutaj MA , Vedi M , Wang SJ , D'Eustachio P , Aimo L , Axelsen K , Bridge A , Hyka-Nouspikel N , Morgat A , Aleksander SA , Cherry JM , Engel SR , Karra K , Miyasato SR , Nash RS , Skrzypek MS , Weng S , Wong ED , Bakker E , Berardini TZ , Reiser L , Auchincloss A , Axelsen K , Argoud-Puy G , Blatter MC , Boutet E , Breuza L , Bridge A , Casals-Casas C , Coudert E , Estreicher A , Livia Famiglietti M , Feuermann M , Gos A , Gruaz-Gumowski N , Hulo C , Hyka-Nouspikel N , Jungo F , Le Mercier P , Lieberherr D , Masson P , Morgat A , Pedruzzi I , Pourcel L , Poux S , Rivoire C , Sundaram S , Bateman A , Bowler-Barnett E , Bye-A-Jee H , Denny P , Ignatchenko A , Ishtiaq R , Lock A , Lussi Y , Magrane M , Martin MJ , Orchard S , Raposo P , Speretta E , Tyagi N , Warner K , Zaru R , Diehl AD , Lee R , Chan J , Diamantakis S , Raciti D , Zarowiecki M , Fisher M , James-Zorn C , Ponferrada V , Zorn A , Ramachandran S , Ruzicka L , Westerfield M . The Gene Ontology knowledgebase in 2023. Genetics 2023; 224(1): iyad031

[36] Wolf FA , Hamey FK , Plass M , Solana J , Dahlin JS , Göttgens B , Rajewsky N , Simon L , Theis FJ . PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. Genome Biol 2019; 20(1): 59

[37] Street K , Risso D , Fletcher RB , Das D , Ngai J , Yosef N , Purdom E , Dudoit S . Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics 2018; 19(1): 477

[38] Ma K , Xu Q , Wang S , Zhang W , Liu M , Liang S , Zhu H , Xu N . Nuclear accumulation of Yes-associated protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression. Cancer Lett 2016; 375(1): 84–91

[39] Klimenkova O , Ellerbeck W , Klimiankou M , Ünalan M , Kandabarau S , Gigina A , Hussein K , Zeidler C , Welte K , Skokowa J . A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation. Blood 2014; 123(8): 1239–1249

[40] Taggart CC , Cryan SA , Weldon S , Gibbons A , Greene CM , Kelly E , Low TB , O’neill SJ , McElvaney NG . Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202(12): 1659–1668

[41] Schubert M , Klinger B , Klünemann M , Sieber A , Uhlitz F , Sauer S , Garnett MJ , Blüthgen N , Saez-Rodriguez J . Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun 2018; 9(1): 20

[42] Fang Z , Meng Q , Xu J , Wang W , Zhang B , Liu J , Liang C , Hua J , Zhao Y , Yu X , Shi S . Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun (Lond) 2023; 43(1): 3–41

[43] García-Palmero I , Torres S , Bartolomé RA , Peláez-García A , Larriba MJ , Lopez-Lucendo M , Peña C , Escudero-Paniagua B , Muñoz A , Casal JI . Twist1-induced activation of human fibroblasts promotes matrix stiffness by upregulating palladin and collagen α1 (VI). Oncogene 2016; 35(40): 5224–5236

[44] Fan C , Zhu W , Chen Y , Zhu W , Ding J . Cancer-associated fibroblasts: origin, classification, tumorigenicity, and targeting for cancer therapy. MedComm (2020) 2025; 6(11): e70415

[45] Chen Y , McAndrews KM , Kalluri R . Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol 2021; 18(12): 792–804

[46] Ma X , Meng Q , Gong S , Shi S , Liang X , Lin F , Gong L , Liu X , Li Y , Li M , Wei L , Han W , Gao L , Liu Z , Zhou X . IL-27 promotes cardiac fibroblast activation and aggravates cardiac remodeling post myocardial infarction. Heliyon 2023; 9(6): e17099

[47] Sallenave JM , Ryle AP . Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. Biol Chem Hoppe Seyler 1991; 372(1): 13–21

[48] Fritz H . Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). Biol Chem Hoppe Seyler 1988; 369(Suppl): 79–82

[49] Abe T , Kobayashi N , Yoshimura K , Trapnell BC , Kim H , Hubbard RC , Brewer MT , Thompson RC , Crystal RG . Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 1991; 87(6): 2207–2215

[50] Mihaila A , Tremblay GM . Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. Z Naturforsch C J Biosci 2001; 56(3-4): 291–297

[51] Sallenave JM , Si Tahar M , Cox G , Chignard M , Gauldie J . Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol 1997; 61(6): 695–702

[52] Westin U , Polling A , Ljungkrantz I , Ohlsson K . Identification of SLPI (secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation. Biol Chem 1999; 380(4): 489–493

[53] Jacoby AS , Melrose J , Robinson BG , Hyland VJ , Ghosh P . Secretory leucocyte proteinase inhibitor is produced by human articular cartilage chondrocytes and intervertebral disc fibrochondrocytes. Eur J Biochem 1993; 218(3): 951–957

[54] Moreau T , Baranger K , Dadé S , Dallet-Choisy S , Guyot N , Zani ML . Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008; 90(2): 284–295

[55] Vogelmeier C , Hubbard RC , Fells GA , Schnebli HP , Thompson RC , Fritz H , Crystal RG . Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 1991; 87(2): 482–488

[56] Hiemstra PS , Maassen RJ , Stolk J , Heinzel-Wieland R , Steffens GJ , Dijkman JH . Antibacterial activity of antileukoprotease. Infect Immun 1996; 64(11): 4520–4524

[57] McNeely TB , Shugars DC , Rosendahl M , Tucker C , Eisenberg SP , Wahl SM . Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90(3): 1141–1149

[58] Nguyen H , Teskey L , Lin R , Hiscott J . Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation. Oncogene 1999; 18(39): 5455–5463

[59] Jin FY , Nathan C , Radzioch D , Ding A . Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997; 88(3): 417–426

[60] Jin F , Nathan CF , Radzioch D , Ding A . Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun 1998; 66(6): 2447–2452

[61] King AE , Morgan K , Sallenave JM , Kelly RW . Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochem Biophys Res Commun 2003; 310(2): 594–599

[62] Lentsch AB , Jordan JA , Czermak BJ , Diehl KM , Younkin EM , Sarma V , Ward PA . Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999; 154(1): 239–247

[63] Greene CM , McElvaney NG , O’Neill SJ , Taggart CC . Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004; 72(6): 3684–3687

[64] Nugteren S , den Uil SH , Delis-van Diemen PM , Simons-Oosterhuis Y , Lindenbergh-Kortleve DJ , van Haaften DH , Stockmann HBAC , Sanders J , Meijer GA , Fijneman RJA , Samsom JN . High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence. Sci Rep 2022; 12(1): 12174

[65] Sun L , Ke M , Wang X , Yin M , Wei J , Xu L , Tian X , Wang F , Zhang H , Fu S , Zhang C . FAP^high α-SMA^low cancer-associated fibroblast-derived SLPI protein encapsulated in extracellular vesicles promotes ovarian cancer development via activation of PI3K/AKT and downstream signaling pathways. Mol Carcinog 2022; 61(10): 910–923

[66] Cheng WL , Wang CS , Huang YH , Liang Y , Lin PY , Hsueh C , Wu YC , Chen WJ , Yu CJ , Lin SR , Lin KH . Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer. Int J Cancer 2008; 123(8): 1787–1796

[67] Yang Y , Rhodus NL , Ondrey FG , Wuertz BR , Chen X , Zhu Y , Griffin TJ . Quantitative proteomic analysis of oral brush biopsies identifies secretory leukocyte protease inhibitor as a promising, mechanism-based oral cancer biomarker. PLoS One 2014; 9(4): e95389

[68] Wang X , Jin Y , Li YX , Yang Y . Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma. Oncol Rep 2018; 39(4): 1793–1804

[69] Wen J , Nikitakis NG , Chaisuparat R , Greenwell-Wild T , Gliozzi M , Jin W , Adli A , Moutsopoulos N , Wu T , Warburton G , Wahl SM . Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am J Pathol 2011; 178(6): 2866–2878

[70] Liang C , Pan W , Zhou Z , Liu X . Identification of prognostic biomarkers of smoking-related lung cancer. J Thorac Dis 2024; 16(2): 1438–1449

[71] Sun J , Li J , Wu Z , Liang Y , Duan R , Zheng M , Wang J , Kong D . SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis. Int J Biol Sci 2022; 18(1): 140–153

[72] Cui C , Chakraborty K , Tang XA , Zhou G , Schoenfelt KQ , Becker KM , Hoffman A , Chang YF , Blank A , Reardon CA , Kenny HA , Vaisar T , Lengyel E , Greene G , Becker L . Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell 2021; 184(12): 3163–3177.e21

[73] Zhu J , Nathan C , Jin W , Sim D , Ashcroft GS , Wahl SM , Lacomis L , Erdjument-Bromage H , Tempst P , Wright CD , Ding A . Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111(6): 867–878

[74] Zheng D , Gui B , Gray KP , Tinay I , Rafiei S , Huang Q , Sweeney CJ , Kibel AS , Jia L . Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene 2016; 35(36): 4807–4815

[75] Kamrava M , Simpkins F , Alejandro E , Michener C , Meltzer E , Kohn EC . Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene 2005; 24(47): 7084–7093

[76] Simpkins FA , Devoogdt NM , Rasool N , Tchabo NE , Alejandro EU , Kamrava MM , Kohn EC . The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis 2008; 29(3): 466–472

[77] Sano T , Hataya T , Terai Y , Shikata E . Hop stunt viroid strains from dapple fruit disease of plum and peach in Japan. J Gen Virol 1989; 70(6): 1311–1319

[78] Devoogdt N , Rasool N , Hoskins E , Simpkins F , Tchabo N , Kohn EC . Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci 2009; 100(3): 434–440

[79] Liu C , Gong J , Zhang Q , Chen G , Yin S , Luo Z , Zeng W , Yu J , Lan P , He Z . Dietary iron modulates gut microbiota and induces SLPI secretion to promote colorectal tumorigenesis. Gut Microbes 2023; 15(1): 2221978

[80] Zhang D , Simmen RC , Michel FJ , Zhao G , Vale-Cruz D , Simmen FA . Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem 2002; 277(33): 29999–30009

[81] Hoskins E , Rodriguez-Canales J , Hewitt SM , Elmasri W , Han J , Han S , Davidson B , Kohn EC . Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol 2011; 122(3): 656–662

[82] Mikami Y , Fukushima A , Komiyama Y , Iwase T , Tsuda H , Higuchi Y , Hayakawa S , Kuyama K , Komiyama K . Human uterus myoma and gene expression profiling: a novel in vitro model for studying secretory leukocyte protease inhibitor-mediated tumor invasion. Cancer Lett 2016; 379(1): 84–93

[83] Chen Y , Zhu S , Liu T , Zhang S , Lu J , Fan W , Lin L , Xiang T , Yang J , Zhao X , Xi Y , Ma Y , Cheng G , Lin D , Wu C . Epithelial cells activate fibroblasts to promote esophageal cancer development. Cancer Cell 2023; 41(5): 903–918.e8

[84] Ji J , Zhao L , Wang X , Zhou C , Ding F , Su L , Zhang C , Mao X , Wu M , Liu Z . Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2004; 130(8): 480–486

[85] Lu Z , Zheng S , Liu C , Wang X , Zhang G , Wang F , Wang S , Huang J , Mao S , Lei Y , Wang Z , Sun N , He J . S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. Clin Transl Med 2021; 11(7): e459

[86] Wang Z , Zhao Y , Wo Y , Peng Y , Hu W , Wu Z , Liu P , Shang Y , Liu C , Chen X , Huang K , Chen Y , Hong H , Li F , Sun Y . The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma. Cancer Lett 2024; 593: 216951

[87] Yao Q , Zhang X , Wang Y , Wang C , Chen J , Chen D . A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma. Eur J Med Res 2024; 29(1): 73

[88] Kawahara R , Bollinger JG , Rivera C , Ribeiro AC , Brandão TB , Paes Leme AF , MacCoss MJ . A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva. Proteomics 2016; 16(1): 159–173

[89] Tarhini M , Pizzoccaro A , Benlyamani I , Rebaud C , Greige-Gerges H , Fessi H , Elaissari A , Bentaher A . Human serum albumin nanoparticles as nanovector carriers for proteins: application to the antibacterial proteins “neutrophil elastase” and “secretory leukocyte protease inhibitor”. Int J Pharm 2020; 579: 119150

[90] Yang M , Chen T , Liu YX , Huang L . Visualizing set relationships: EVenn’s comprehensive approach to Venn diagrams. iMeta 2024; 3(3): e184

RIGHTS & PERMISSIONS

Higher Education Press